title: [PEG IFN alpha-2a in the treatment of chronic hepatitis C in patients with treatment failure].
abstract: Despite the significant advances that have been made in the treatment of chronic hepatitis C the efficacy of treatment response seems to be unsatisfactory. Treatment failure concern above one half of treated patients. It is estimated that the number of non-responders will be systematically increased. For these reasons as treatment strategies in these patients there is a need to define optimal way to use new therapies as: extending of treatment duration, higher initial doses of administered medications, an increase of patients adherence, changing of kind of pegylated interferon or treatment combinations PEG IFN + RBV with other drugs, especially HCV-enzymes inhibitors. In the work the data of efficacy of retherapy with PEG IFN alfa-2a+RBV administered during 72 weeks were present. Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. In the future there are planned treatment of chronic hepatitis C with combined therapy with IFN, specific HCV-enzymes inhibitors and antiviral medications.
authors: Katedra i Klinika Chorób Zakaźnych i Hepatologii, Collegium Medicum Uniwersytetu Mikołaja Kopemika w Toruniu. kikchzak@cm.umk.pl
authors: Małgorzata
authors: M
authors: Pawłowska
authors: Waldemar
authors: W
authors: Halota
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a